Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by stockbuphoonon Mar 19, 2020 1:35am
118 Views
Post# 30824894

RE:RE:The plant checkpoints are obviously done:

RE:RE:The plant checkpoints are obviously done:https://seekingalpha.com/article/4306384-liminal-biosciences-pfscf-ceo-ken-galbraith-on-q3-2019-results-earnings-call-transcript?part=single

This is straight out of Q3 transcript. Can't believe some here who post daily have not checked simple transcripts when some are on here everyday. Has anyone talked to anyone at company to confirm or deny what Galbraith said? This is very old news. Cheers, folks. Protect your elders through Covid 19 peak:

"R&D expenses were $63 million during the nine months ended September 30, 2019 compared to $70.5 million for the corresponding period in 2018, representing a decrease of $7.6 million. This difference is explained by the reduction in spending with third parties on clinical and preclinical studies and the
completion of analytical assay validation and in process controls in the manufacturing of Ryplazim amounting to $9.2 million."

"R&D expenses were $19.6 million during the quarter ended September 30, 2019, compared to $24.1 million for the corresponding period in 2018, representing a decrease of $4.5 million. As mentioned previously, this is mainly due to lower expenses in the development of Ryplazim"

"Also, we're making excellent progress with the ongoing work to support the filing of our BLA for Ryplazim and are confident in our ability to file the BLA during the first half of 2020, as previously disclosed. Much of the work to achieve that milestone is behind us and we look forward to discussing our proposed filing with the FDA in a formal, pre-BLA meeting to be held in 2020." 

GunnerG wrote: Realstups, your good at cut and paste, post a company NR or FDA NR stating they are completed.

You can't because THEY HAVE NOT BEEN COMPLETED.

Those 9,000 shares you bought days ago have lost a good chunk of money, told you to early.

Once again you have shown yourself to be a doofus.





<< Previous
Bullboard Posts
Next >>